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SUMMARY
Background. A previous two-year study o f continuous and 
on demand bronchodilator therapy in patients with moder­
ate asthma and chronic bronchitis showed a deterioration 
in lung function in those on continuous therapy.
A im . A two-year fo llow -up s tudy was undertaken of 
patients who had been shown in the previous study to have 
non-steroid dependent (mild) asthma and chronic bron­
chitis, in order to investigate the effect of continuous and 
on-demand treatment with bronchodilator therapy.
Method. Patients for the study were drawn from 29 general
was 49 ml year1 in patients taking bronchodilators continu­
ously and 51 ml year1 in patients using bronchodilators on 
demand, irrespective of the drug used. Continuously treat­
ed patients, whether suffering from asthma or chronic 
bronchitis, did not differ from patients treated on demand 
with respect to mean morning peak flow rater diurnal (and 
week to week) variation of the peak flow rate, bronchial 
hyper-responsiveness, exacerbation rate and reported  
health. There was no difference between the long-term  
effects ofsalbutamol and ipratropium.
Conclusion. Continuous use o f bronchodilators over four 
years in patients with non-steroid dependent asthma or 
chronic bronchitis does not increase the decline in lung 
function which had been observed previously in patients 
with moderate asthma or chronic bronchitis during two 
years of continuous treatment with bronchodilators.
Keywords: asthma; bronchitis ; bronchodilators; drug
administration; drug dosage; lung function.
Introduction
PIDEMIOLOGICAL studies of patients with moderate or 
severe asthma or chronic bronchitis have painted to an asso­
ciation between the prescription of beta2-udrenergic drugs and 
death from asthma.1,2 Although epidemiological studies cannot
practices in the catchment area o f  the Univers ity  o f  provide evidence that bronchodilators themselves increase
Nijmegen, the Netherlands. A total of 83 patients (27 with 
asthma and 56 with chronic bronchitis) were selected from 
a group of 160 patients who had completed the previous 
two-year bronchodilator trial. During these first two years 
the selected subjects had been shown to be non-steroid 
dependent (no rapid decline in lung function and a low  
number o f exacerbations of their condition per year), and
asthma mortality, these studies have caused considerable concern 
about the possible deleterious effects of long-term continuous 
use of bronchodilators. This concern increased when two 
prospective randomized trials were published which showed an 
increase in bronchial hyper-responsiveness-’ and in decline in
with continuous use of hronchodilators. These and 
earlier observations led to the recommendation in several
4
demand.5,6 It is not clear whether the continuous use of bron 
chodilators over a period of several years might also have delete­
rious effects in patients with mild asthma or chronic bronchitis.
General practice patients with mild asthma or chronic bron­
chitis might be non-steroid dependent and most of these patients 
in the Netherlands are treated with bronchodilators only7 “•
they were followed up for another two years of treatment in ternational gu idelines only to use b ronchod ila to rs  on
with bronchodilator therapy. At the start o f the four-year 
study, patients were randomly assigned to one of two par­
allel treatment groups: continuous treatment (dry powder 
inhalations of either salbutamol 1600 fig or ipratropium  
bromide 160 fig daily) or treatment on demand (only during
exacerbations or periods o f dyspnoea). Outcome para­
meters were the annual decline in lung function, changes in probably the case in many other countries. It could be that the
peak flow rate, bronchial hyper-responsiveness, exacerba- adverse effects of the continuous use of bronchodilators are not,
tion rate, respiratory symptoms and reported health. or are less clearly, present in patients with non-steroid dependent
Results, After correction for possibly confounding variables asthma or chronic bronchitis. Thus far, adverse effects have main-
and for regression to the mean, the decline in lung function ty been reported with beta-adrenergic drugs. It is important to
assess whether these effects are common to all bronchodilators.
The first aim of this study was to investigate the effect of con­
tinuous and on demand treatment with bronchodilators over four 
years in patients with non-steroid dependent asthma or chronic
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bronchitis. The second aim was to compare the long-term effects 
of the anticholinergic drug ipratropium bromide with those of the 
beta,-adrenergic d ru g  salbutamol. The sample of patients was 
drawn from the population of patients who had already been fol-
two years.4
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M eth o d
Patients
The study began in 1987. Patients aged 30 years and over were 
drawn from 29 practices in the catchment area of the University 
of Nijmegen, the Netherlands. A description of the original 
patient selection is given elsewhere.4 01' 223 participating 
patients, 160 completed the first two years of bronchodilator 
treatment.4 It was considered unethical to continue bronchodi­
lator treatment in patients who had been shown to need addition­
al anti-inflammatory medication because of a clear progression
the end of a randomly chosen four-month period.11 
of compliance continued independently of this substudy; 
were unaware that their medication was being counted after 
period.
Lung function, bronchial responsiveness and airways 
reversibility
All measurements were carried out by two qualified laboratory 
assistants during exacerbation-free periods. No bronchodilator 
was inhaled for at least eight hours before the pulmonary func- 
of their disease. Therefore 56 patients (27 using bronchodilators tion tests. The FEV ^ bronchial responsiveness to histamine 
on demand and 29 using them continuously) with a rapid decline (PC2o histamine values) and the reversibility of airways obstruc- 
in forced expiratory volume in one second (FEV|) 0 8 0  ml tion were assessed at six-m onth intervals by means of the 
y ea r1) and an exacerbation rate of more than one episode per Microspiro HI-298® (Chest Corporation).12 The FEVi and air-
year were withdrawn from this study and received an inhaled ways reversibility were also assessed after one and 13 months of
corticosteroid.8 The remaining 104 patients were asked to contin- study.4 The best of three forced expiratory manoeuvres, with the 
ue in the study for another two years with only bronchodilator highest sum of the forced vital capacity and FEVi, was used for
treatment. These patients were considered non-steroid dependent. 
Of these patients 21 refused to participate and 83 continued. All 
of the 21 patients who refused did so because of personal reasons 
unrelated to their disease. Their clinical status was not different 
from the 83 patients who continued the study.
The criteria for the diagnosis of asthma or chronic bronchitis 
were based on those of the American Thoracic Society.9 Asthma 
was defined as the combination of: bronchial hyper-responsive­
ness to histamine (provoking concentration of histamine that pro­
duces a 20% decrease in FEVi (PC20) < 8  mg histamine ml’1); 
reversible airways obstruction (FEVi improved by more than 
15% of the pre-bronchodilator value 60 minutes after the admin­
istration of both salbutamol 400 jig and ipratropium bromide 
80 jig); dyspnoea; allergy (at least one positive test out of seven 
of the most common radioallergosorbent tests) and/or wheezing. 
Chronic bronchitis was defined as the combination of: chronic 
cough or chronic sputum production for at least three months 
during at least two consecutive years; and continuous bronchus 
obstruction (FEVi *£85% of the predicted value10).
Although separate features of asthma and chronic bronchitis 
were n o t  m utually exclusive (for example, some asthma 
patients had chronic cough and some chronic bronchitis patients 
had a PC20 < 8  mg ml*1, the combination of features was such 
that no patient with asthma also had chronic bronchitis and vice 
versa.
data analysis. Bronchial responsiveness to histamine was meas­
ured according to the method described by Cockcroft and col­
leagues. 13
Peak expiratory flow  rate assessments and exacerbations
Once a week, peak expiratory flow rate measurements were per­
form ed w ith the  Assess® peak flow m eter (H ealthscan 
Products)14 at home in the morning and evening, on the same day 
and at the same time. The highest value out of three measure­
ments was taken for analysis. The diurnal peak expiratory flow 
rate index (absolute difference between evening value and morn­
ing value divided by the highest value) and the week-to-week 
variation in the peak expiratory flow rate (the standard deviation 
expressed as percentage of the mean moniing peak flow in three 
months) were calculated.
Exacerbations were defined according to Fletcher with the 
small modifications of Boman and colleagues,15 and comprised 
(muco)purulent sputum, cough and at least one of the following 
symptoms: general malaise, symptoms of common cold, fever, 
dyspnoea, increased sputum production, increased sputum thick­
ness, foul-tasting sputum or increased difficulty in expectorating, 
In case of an exacerbation, a 10-day course with oral pred­
nisolone was given. Patients received 25 mg for two days, 20 mg 
for two days, 15 mg for two days, and so on.
Study design and treatment protocol
The study was approved by the medical ethics committee of the 
University of Nijmegen. AU patients gave informed consent. At 
the start of the four-year intervention study, and after an eight- 
week washout period patients were randomly allocated to one of 
two parallel treatment regimens: continuous bronchodilator ther­
apy (four times daily) or treatment on demand (only during 
periods of complaints).4 During the first two years the patients 
used dry powder inhalations of salbutamol 400 |J.g during one 
year and of ipratropium bromide 40 fig during the other year. 
The sequence of the drugs was determined by random allocation. 
During the third and fourth years, the 83 patients continued the 
medication they had been taking in the second year.
Patients had to record all the medication they used in a diary. 
Once every three months throughout the study period, the inhala­
tion technique as well as compliance with the prescribed medica­
tion were checked by the general practitioner or practice assist-
Symptoms, health and smoking habits
Respiratory symptoms were assessed by means of a Medical 
Research Council questionnaire at the beginning, after 24 months 
and at the end of the study, and quantified on a scale of 0-8.7 
Additionally, all patients made weekly recordings of the pres­
ence and severity of symptoms (cough, phlegm, dyspnoea) on a 
scale of 0-4.
Health (energy, pain, emotions, sleep, social limitations and 
mobility problems) was assessed by means of the Nottingham 
health profile at the start of the study, after 24 months and at the 
end of the study.16 At the start of the study, smoking history was 
assessed in pack years (by multiplying number of years smoking 
cigarettes and reported number of cigarettes smoked per day, 
divided by 20). During the study, the average number of cigar­
ettes smoked per day was also recorded in the diary every week.
Power calculations
ant. Any deviations from the protocol were discussed immediate- On the basis of the earlier study4 it was assumed that a clinically 
ly with the patients. A separate, single-blind, prospective study relevant difference in decline in FEVf (the primary effect para- 
was carried out assessing bronchodilator therapy compliance meter) between the two parallel treatment groups was 40 ml 
among patients who used the drug continuously. Compliance 
was measured by research investigators who counted capsules at
year With
With
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sided) and a beta of 0.20 (power of (1 -  0.2) = 0.8), the required 
number of patients per group was 30. With an estimated drop-out 
rate of 20%, the required initial number of patients in both 
groups was 36.
Results
Analysis
Values of outcome variables between the two treatment groups 
were tested by multivariate analysis of variance for normally dis­
tributed variables and the Wilcoxon test for not normally distrib­
uted variables. All FEVi and PC20 values were adjusted for 
vsm oking behaviour before and during the study, for sex, age.
height, allergy, initial FEVi (% predicted) and initial PC21». Prior 
to analysis, the PC20 values were -log transformed. The annual 
changes in FEVi and PC20 were calculated by linear regression 
of individual FEV, and 2logPC2n values in the course of time. To
determine the group values, the individual regression coefficients 
were averaged. The weekly measured peak expiratory How rate 
was averaged for three-month periods. Patients with asthma and 
chronic bronchitis were analysed together and separately.
Of the 83 patients who completed the study, six patients did 
not use the planned study medication or used additional medica­
tion. Therefore, both explanatory analysis (only those patients 
included who used only the study medication) and intention to 
treat analysis (all patients included) were performed. Unless 
these two analyses had different outcomes, only the results of the 
intention to treat analysis are given.
In the present study design, patients were not randomly select­
ed from the original study population: only patients with a less 
severe form of the disease were selected. By chance these 
patients might have deteriorated during the third and fourth years 
when compared with the two first years of treatment. This phe-
r is t ies
Of the 83 patients who completed the four-year study, 77 com­
pleted it with the planned study medication. Of the other six 
patients, five needed additional medication in the fourth year, 
(three received an inhaled steroid and two were given sodium 
cromoglycate) and one refused to continue taking salbutamol 
continuously in the fourth year. These six patients were not 
excluded from the study. At the start of the study there was no
between these six patients and
the other 77 patients.
Of the 83 patients, 27 had asthma and 56 had chronic bron­
chitis. There were significantly more smokers among patients 
with chronic bronchitis than among patients with asthma, and 
asthma patients were significantly more likely to have an allergy 
(Table 1). Of the patients who completed the four-year study 36 
were taking bronchodilators continuously and 47 were taking 
bronchodilators on demand. In the second, third and fourth years 
of the study, 48 patients were on ipratropium, of whom 21 were 
taking it continuously, and 35 were on salbutamol of whom 15 
were taking it continuously. The four treatment groups were 
comparable in every respect at the start of the four-year interven­
tion study (Table 1).
Broncho dilator use, and smoking behaviour ¿luring study
Patients treated on demand used a median of 0.1 (range 0.1-2.0) 
dry powder inhalations of salbutamol per day and 0.1 (range 
0.1-1.3) inhalations of ipratropium per day, which was not sig­
nificantly different. The single-blind study of compliance among 
patients on continuous bronchodilator medication showed that 
mean individual compliance rates were 98% (standard deviation
nomenon is called regression to the mean. The influence of 29%) of the prescribed medication.
regression to the mean was calculated for both treatment groups 
in separate analyses. The effect of regression to the mean was 
estimated by the equations of Davis.17
The effects of ipratropium and salbutamol on all outcome 
parameters were assessed by comparing the effects during years 
two to four, as the medication had been crossed after the first 
year. This was only done if no interaction effect between the 
treatment regimen and the drug could be detected.
The median number of cigarettes smoked during the study by 
patients using bronchodilator therapy on demand was 0 per day 
(range 0-28) and by patients using bronchodilators continuously, 
four per day (range 0-21) (?<0.05).
Lung function 
Grouping patients with asthma i •onic
the annual decline in FEVi over the four years was 70 ml year
KWH»** up imburri wn *****
Table 1. Baseline characteristics of patients who completed the study, according to diagnosis and treatment in the second, third and 
fourth years of the study.
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Patients with Salbutamol Ipratropium
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Variable
Asthma Chronic On demand Continuously On demand Continuously
(n » 27) bronchitis (n « 56) (n -  20) (n®15) (/i®27) (n = 21)
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51 (12) 53 (14) 49(13) 54(17) 50 (14) 57 (9)
15 34 8 10 17 14
27/0 0/56 8/12 6/9 6/21 7/14
6 (0-75) 12 (0-81) 8(0-73) 15(0-75) 7 (0-81) 18 (0-52)
18 48* 15 12 20 19
4.7 (1.9) 4.6 (1.7) 4.9 (1.7) 4.8 (2.0) 4.6 (1.9) 4.3 (1,6)
11 10* 8 4 8 1
2.4 (0.9) 2.6 (0.9) 2.6 (0.8) 2.3 (0.9) 2.7 (0.9) 2.3 (0.8)
15(0-54) 6(0-40)** 9(0-25) 71 ( 1-47) 8(0-40) 7(0-54)
2.9 15.2*** 8.8 7.1 13.8 7,9
Mean (SD) age (years)
No. of men 
No. with asthma/ 
chronic bronchitis 
Median no. (range) of 
of pack years 
No. of smokers 
Mean (SD) respiratory 
symptom score 
No. with allergy 
Mean (SD) FEVi (I)
Median (range) reversibility 
(% FEVi predicted)
PC20 (mg histamine ml'1)
n » number of patients in group. SD ■ standard deviation. Difference between patients with asthma and chronic bronchitis: *P<0.05, * #P<0.01, 
***P<  0.001.
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in patients using bronchodilators on demand and 60 ml year'1 in
patients using bronchodilators continuously. This difference was 
not significant (10 ml, 95% confidence interval (Cl) -21 to 41 ml 
year"1). After correction for possibly confounding variables the 
decline was 66 ml y ea r1 in patients using treatment on demand 
and 65 ml year'1 in patients using treatment continuously. The 
estimated regression to the mean effect was approximately the 
same in both groups: 29 ml year"1 in patients using treatment on 
demand and 32 ml y ea r1 in patients using treatment continuous­
ly. After correction for this regression effect the annual decline 
over the four years was 51 ml year'1 among patients taking bron­
chodilators on demand and 49 ml y e a r1 among patients using 
bronchodilators continuously.
The mean change in FEVi and standard error over the four 
years for patients with asthma are shown in Figure 1, and for 
those with chronic bronchitis in Figure 2 (while the standard 
error is plus and minus the mean, in order to keep the figures 
clear, the standard error has been marked as plus the mean for
A sthm a
3500
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• Mean
IT Standard error Treatment on demand
y -  -28.3x + 2 1 M
>
LU
I
2 0 0 0 -
1500- Continuous treatment 
y  =s -43.3x + 2039
I
0 0.5 1 ,0 1.5 2 .0 2.5 3.0 3.5 4.0
No. of years from start of study
Figure 1. Course of FEV, (mean and standard error) over four
patients on treatment on demand, and minus the mean for years in patients with asthma, of whom 13 were on continuous
patients on continuous treatment). Patients who used bron­
chodilators on demand did not differ significantly from those 
treated continuously (corrected mean values for asthma: 21 ml
and 14 were using on demand treatment
r ■■I—
1
3500
3000-
• Mean
JIT Standard error
2500
E
r ~
fu 2 0 0 0
1500-
0 0.5 1 .0
year'1 versus 58 ml y e a r1 respectively, and for chronic bron­
chitis: 85 ml year'1 versus 60 ml year'1 respectively).
The mean decline in FEV i among patients on salbutamol was 
not significantly different from the mean decline among among 
those using ipratropium (difference 2 ml year'1, 95% Cl -71 to 
75 ml year'1).
Peak expiratory flow rate
During the study the mean morning peak expiratory flow rate of 
asthma patients using bronchodilators continuously did not differ 
significantly compared with patients using treatment on demand
(15 ml year'1 Cl difference, 95% -10 to 40 ml year1), nor was 
there a difference in diurnal index between the two groups, the 
mean diurnal index in patients using bronchodilators on demand 
being 11.6% and in those using bronchodilators continuously 
10.4% (difference 1.2%, 95% Cl -2.9% to 5.3%). The week to 
week variation in peak expiratory flow rate in asthma patients 
using treatment on demand was not significantly different from 
that o f patients using treatment continuously (12.4% versus 
10.6% respectively, difference 1.8%, 95% Cl -1.1% to 4.7%).
Among patients with chronic bronchitis no difference was 
observed in the mean morning peak flow according to treatment 
method (difference 2 ml y ea r1, 95% Cl -12 to 16 ml year1). The 
mean diurnal index among patients with chronic bronchitis using 
bronchodilators continuously was 8.5% and among patients 
using treatment on demand 6.1% (difference 2.4%, 95% Cl 
-0.1% to 4.9%)). The week to week variation in peak expiratory 
How rate was 8.6%' in both groups of patients.
Among patients using salbutamol, mean morning peak expirat­
ory flow rate was 405 1 min'1, which was not significantly differ­
ent from the mean morning rate of 428 1 min'1 among those using 
ipratropium (difference 23 1 min'1, 95% Cl -30 to 76 I min'1).
The same applied to the diurnal index of the peak expiratory 
flow rate (9.3%) versus 7.2%, respectively) and to week to week 
variation (8.5% versus 8.3%, respectively).
Bronchial hyper-responsiveness
The course of PC2() for patients with asthma and chronic bronchi­
tis is shown in Figure 3. Among patients with asthma, there was 
a slight increase in bronchial hyper-responsiveness in patients 
treated on demand: the mean change in PC2() over the four years 
was -0.64 doubling dose of histamine per year. In patients using 
bronchodilators continuously it was 0.01 doubling dose per year (n = number of patients).
Chronic bronchitis
Treatment on demand
y  =  -8 7 .1 X +  2751
Continuous treatment 
y  = -68.9x + 2467
1.5 2.0 2.5 3.0 3.5 4.0
No. of years from start of study
Figure 2. Course of F£V, (mean and standard error) over four 
years in patients with chronic bronchitis of whom 23 were on 
continuous and 33 were using on demand treatment.
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Figure 3. Bronchial hyper-responsiveness (course of PCSJ 
over four years in patients with asthma and chronic bronchitis
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(difference 0.65, 95% Cl -0.09 to 1.39 doubling dose per year). 
In patients with chronic bronchitis these changes were compar­
able (-0.36 versus -0.44 doubling dose per year, respectively).
Although at present there is evidence of a possible correlation 
between the use of bronchodilators and asthma-related death,1,2 it 
is not probable that the relationship is causal in this way. It is
Among patients using salbutamol, the mean change in PC2„ for more probable that overdependence on the beta2-adrenergic
asthma was -0.29 doubling dose per year, which was not signific­
antly different from the mean change of -0.51 doubling dose per 
year among patients using ipratropium (difference 0.22, 95% Cl 
-0.77 to 1.21 doubling dose per year). Among patients with
drugs delays the use of necessary anti-inflammatory agents 
which then might be a cause of death from asthma,19
The results of the study should be interpreted with caution. 
The findings do not justify the conclusion that all patients with
chronic bronchitis there was an increase in PC2() when salbutamol mild asthma or chronic bronchitis should be treated with only
was used and a decrease when ipratropium was used (0.44 versus 
-0.94 doubling dose per year, respectively). This difference was
bronchodilators, without anti-inflammatory treatment. Five of the 
83 selected patients (6%) who had been shown to be non-steroid
significant (1.38 doubling dose per year, 95% Cl 0.27 to 2.44 dependent during the first two years needed additional anti­
doubling dose per year). inflammatory medication in the fourth year. Moreover, it is not 
known what would have happened if all the patients in the pres­
ent study had received additional anti-inflammatory treatment. 
During the study the number of exacerbations in patients who As far as is known there is only one other long-term study in 
used bronchodilators on demand decreased from 0.7 in the first
Exacer
That study clearly showed that
year to 0.5 in the fourth year. The number of exacerbations in bronchial hyper-responsiveness improved considerably during
those taking bronchodilators continuously showed an opposite 
trend: an increase from 0.5 to 0.7 from the first to the fourth year. 
However, the difference was small and non-significant. There 
was no difference between patients with asthma and chronic 
bronchitis in this respect.
The mean number of exacerbations in patients using salbuta­
mol was not significantly different from the number in those 
using ipratropium (0.6 versus 0.5 exacerbations per year, respect­
ively).
Recorded symptoms and health
The severity of weekly recorded symptoms decreased in patients 
using bronchodilators on demand when compared with those 
using bronchodilators continuously (difference 0.4 points per 
year on the symptom score, 95% Cl 0 to 0.8 points per year). 
When respiratory symptoms were measured on the Medical 
Research Council questionnaire this observation was confirmed: 
a decrease of 0.3 points per year in patients using bronchodi­
lators on demand which differed significantly from the increase 
of 0.1 point per year in patients using bronchodilators continu­
ously (difference 0.4, 95% Cl 0.1 to 0.7 points
The weekly symptom score showed the same change among 
those using salbutamol as among those using ipratropium (a
. 1 point per
Health as measured on the Nottingham health profile was not 
influenced by treatment regimen or by drug.
Discussion
The main results of this study indicate that continuous use of
s over lour years in patients with non-steroid
dependent asthma or chronic bronchitis does not seem to 
increase decline in lung function. This is contrary to the observa­
tions in a previous study in which patients with steroid-depencl-
¡ \ 1 1 4
It is important to assess what may have caused the difference 
between the findings in the present study of patients with non­
steroid dependent asthma and chronic bronchitis and those in the 
earlier studies in which increased hyper-responsiveness-1 and 
increased decline in lung function4 were found among those using 
bronchodilators continuously. The most likely explanation is in 
the selection of patients for the present study: only those patients 
who had been shown to be non-steroid dependent during the first 
two years of study were selected. The hypothesis was that in these 
patients the possibly harmful effects of continuous use of bron­
chodilators would not be (or would be less clearly ) present.
The present study does not seem to point to a direct link 
between the continuous use of bronchodilators and an increase in 
asthma morbidity or mortality, the so-called asthma paradox,18
the 12-month use of an inhaled steroid in 15 of 16 asthmatic 
patients. On the other hand, the results of that study do not seem 
to justify the early introduction of inhaled steroids in all non­
steroid dependent asthma patients. The 16 patients studied were 
selected when they attended a clinic because of pulmonary prob­
lems. Moreover, all of them used bronchodilators more than once 
daily. In the present study, 14 of the 83 patients (17%) had once 
attended a clinic for pulmonary problems and only 24 patients 
(29%) had used bronchodilators continuously before the start of 
the study,4,7 The remaining patients had used bronchodilators on 
demand in the year preceding this four-year study.4
It is estimated that in the Netherlands7 and in the United
Kingdom*1 at least 80% of all patients with asthma or chronic 
bronchitis are treated in primary care. This is particularly so for 
patients with mild forms of asthma. On the basis of the results of 
the present study it seems probable that there are patients with
forms of airway obstruction who do not (yet) need anti- 
atory drugs. Symptomatic use of bronchodilators might 
be sufficient for these patients. The inflammatory processes 
underlying the progression of the disease are probably not at a
ammatory treatment is necessary. This is in 
ance with recently developed guidelines which advise 
anti-inflammatory treatment when bronchodilators are needed on 
a regular basis (more than once daily).5 In a random sample of 
patients with asthma or chronic bronchitis in primary care it was 
observed that only 42% used bronchodilators continuously.7 This 
figure shows that there may be a considerable number of patients 
who are in an early phase of the disease and who do not yet need 
anti-inflammatory drugs. As it is still not clear whether chronic 
use of inhaled steroids will have
long run, caution is necessary in prescribing drugs on a long
in
Isa
It is difficult to know how to distinguish between patients who 
do and do not need anti-inflammatory medication. This problem
the low correlation between 
the progression of the disease and the perception of symptoms2- 
and experienced health.1'’ It seems that most patients learn to live
•23 it is import-II
ant to instruct patients to consult
•s daily.5 The general practitioner
anti-
s to a s
In order to detect patients with a rapid progression of asthma
onic bronchitis in primary care, regular testing of pul-
in general practices is advised. In this study the 
were found to be steroid-dependent after two
ary
56 patients
te4
were detected on the basis of regular lung function test- 
These 56 patients were part of the original group of 223
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patients (25%) who at the start of the study were considered to be 
non-steroid dependent by their general practitioner.4 Additional 
treatment with steroids clearly slowed down the deterioration 
caused by asthma and chronic bronchitis in these patients.8
The definition of asthma and chronic bronchitis was based on 
the standards of the American Thoracic Society.9 The accuracy 
of this definition was confirmed by the results of this study: as 
expected, the yearly decline in lung function was at least twice as 
high in patients with chronic bronchitis as in those with asthma, 
despite the more impaired clinical condition of the asthma 
patients, at the start of the study (shown by their lung function, 
airways reversibility and bronchial hyper-responsiveness values). 
Moreover, it was observed that asthma patients had a higher 
diurnal variation of the peak flow, they smoked less before and 
during the study and they responded much better to inhaled cor­
ticosteroids.8 Smoking behaviour, diurnal variation of the peak 
flow and steroid responsiveness were not used in the present 
study’s definition criteria, but are all important characteristics for 
distinguishing between asthma and chronic bronchitis.
One of the problems in such a study is that the selection pro­
cedure could have biased the results. Patients with a rapid 
decline in lung function (^ 8 0  ml year"1) and an exacerbation 
rate of more than one episode per year were excluded from par­
ticipation in this study.8 Because of this one-sided selection pro­
cedure the decline in lung function of the patients participating 
in this study may have increased because of statistical reasons 
unrelated to the disease (regression to the mean effect). The data 
for the decline in lung function were corrected for this effect. 
The most important question is whether the regression effect in 
patients treated on demand was different from that of patients 
treated continuously. As these effects were comparable it can be 
concluded that the selection procedure did not bias the main 
results of the study.
The second aim of this study had been to compare the long­
term effects of salbutamol and ipratropium bromide. There was 
no difference between the drugs in all the investigated parame­
ters, with one exception: bronchial hyper-responsiveness 
decreased with the use of salbutamol and increased with the use 
of ipratropium in patients with chronic bronchitis. It is difficult 
to give an explanation for this finding, but it may be explained
5.
by the inhibition of mediator release from neutrophils, which has 
been found in in vitro experiments.2S As patients with chronic 
bronchitis who smoke are known to have elevated numbers of 
neutrophils in bronchoalveolar lavage fluids and biopsies,26 this 
might explain the favourable effect of salbutamol on hyper­
responsiveness in chronic bronchitis. However, a more likely 
explanation is that it is just a coincidental finding, as multiple 
comparisons were made in this study.
In conclusion, the continuous use of bronchodilators over four 
years in patients with non-steroid dependent asthma or chronic 
bronchitis does not seem to increase the decline in lung function 
as had been observed in patients with moderate asthma or chronic 
bronchitis. There was no difference found between the long-term 
effects of salbutamol and ipratropium bromide.
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